{
  "id": "glp-1-products",
  "title": "GLP-1 products and trial candidates",
  "note": "Six selected formulations and candidates, not the complete GLP-1 pipeline. US label information and sponsor trial reports are different source types. This is not an efficacy comparison or prescribing guide.",
  "headers": [
    "Product / molecule",
    "Form in the source",
    "US label or trial status"
  ],
  "rows": [
    [
      "Wegovy injection · semaglutide",
      "Weekly injection",
      "US-labelled formulation"
    ],
    [
      "Wegovy pill · semaglutide",
      "Daily tablet",
      "US-labelled formulation"
    ],
    [
      "Zepbound · tirzepatide",
      "Weekly injection",
      "US-labelled formulation"
    ],
    [
      "Foundayo · orforglipron",
      "Daily pill",
      "FDA approval: 1 April 2026"
    ],
    [
      "Retatrutide",
      "Weekly injection in trials",
      "Investigational; not an FDA-approved drug"
    ],
    [
      "CagriSema",
      "Weekly injection in trials",
      "Phase 3 sponsor report; not a product label"
    ]
  ],
  "page": "https://stemcellatlas.com/en/quiz/new-glp-1-comparison",
  "snapshot_date": "2026-08-30",
  "sources": [
    "https://investor.lilly.com/node/54321/pdf",
    "https://pi.lilly.com/us/zepbound-uspi.pdf",
    "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218316s002lbl.pdf",
    "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss",
    "https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program",
    "https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916501"
  ],
  "sources_by_row": [
    [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218316s002lbl.pdf"
    ],
    [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218316s002lbl.pdf"
    ],
    [
      "https://pi.lilly.com/us/zepbound-uspi.pdf"
    ],
    [
      "https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program"
    ],
    [
      "https://investor.lilly.com/node/54321/pdf",
      "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"
    ],
    [
      "https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916501"
    ]
  ],
  "registry_records": [],
  "version": "2026-08-30.1",
  "scope": "Six selected formulations and candidates, not the complete GLP-1 pipeline. US label information and sponsor trial reports are different source types. This is not an efficacy comparison or prescribing guide.",
  "modifications": "Figures reproduce selected, source-linked tables already reviewed by StemCellAtlas. The GLP-1 table selects name, form and status from the reviewed comparison tool. No source records were altered and no new clinical results were added.",
  "rights": "You may reuse these StemCellAtlas-created figures and captions with source attribution. This permission does not cover the underlying papers, registry records or third-party works. Keep the snapshot date and scope note when quoting a figure."
}